Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -10% Improvement Relative Risk ICU admission -110% Hospitalization time -10% Sullerot et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 1,047 patients in multiple countries (Mar - Dec 2020) Higher ICU admission (p=0.007) and longer hospitalization (p=0.024) Sullerot et al., GeroScience, doi:10.1007/s11357-021-00499-8 Favors aspirin Favors control
Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia
Sullerot et al., GeroScience, doi:10.1007/s11357-021-00499-8
Sullerot et al., Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia, GeroScience, doi:10.1007/s11357-021-00499-8
Jan 2022   Source   PDF  
  All Studies   Meta
Retrospective 1,047 pneumonia patients in 5 COVID-19 geriatric units in France and Switzerland, significantly higher ICU admission and longer hospital stays with existing aspirin treatment. Numbers in this study appear to be inconsistent, for example the abstract says 147 of 301 aspirin patients died, shown as 34.3%, while Table 1 shows 104 of 301 (34.6%).
risk of death, 10.0% higher, RR 1.10, p = 0.52, treatment 101 of 301 (33.6%), control 224 of 746 (30.0%).
risk of ICU admission, 109.7% higher, RR 2.10, p = 0.007, treatment 22 of 301 (7.3%), control 26 of 746 (3.5%).
hospitalization time, 10.0% higher, relative time 1.10, p = 0.02, treatment 301, control 746.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sullerot et al., 7 Jan 2022, retrospective, propensity score weighting, multiple countries, peer-reviewed, 15 authors, study period 1 March, 2020 - 31 December, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: GeroScience ORIGINAL ARTICLE Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS‑CoV‑2 pneumonia Coralie Sullerot · Kevin Bouiller · Caroline Laborde · Marine Gilis · Amélie Fèvre · Arthur Hacquin · Patrick Manckoundia · Florence Hoefler · Messaline Bermejo · Aline Mendes · Christine Serratrice · Virginie Prendki · Stéphane Sanchez · Alain Putot · On behalf of ESGIE (European Society of Clinical Microbiology, European Society of Clinical Microbiological and Infectious Diseases, Study Group for Infections in the Elderly) Received: 21 September 2021 / Accepted: 13 December 2021 © The Author(s), under exclusive licence to American Aging Association 2021 Abstract Platelet aggregation has been associated with COVID-19 pathogenesis. In older patients hospitalized for SARS-CoV-2 pneumonia, we aimed to investigate the association between aspirin use before admission and the risk of in-hospital all-cause mortality. We performed a retrospective international cohort study in five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive hospitalized patients aged 75 or older and testing positive for SARS-CoV-2, we included 1,072 with radiologically confirmed pneumonia. To adjust for confounders, a propensity score for treatment was created, and stabilized inverse probability of treatment weighting (SIPTW) was applied. To assess the association between aspirin use and in-hospital 30-day mortality, SIPTW-adjusted Kaplan–Meier and Cox proportional hazards regression analyses were performed. Of the 1047 patients with SARS-CoV-2 pneumonia and median age 86 years, 301 (28.7%) were taking aspirin treatment before admission. One hundred forty-seven (34.3%) patients who had taken aspirin died in hospital within 1 month vs 118 patients (30.7%) without aspirin. After SIPTW, aspirin treatment was not significantly associated with lower mortality (adjusted hazard ratio: 1.10 [0.81–1.49], P = .52). Moreover, patients on aspirin had a longer hospital stay and were C. Sullerot · A. Hacquin · P. Manckoundia · A. Putot Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, France A. Mendes Division of Geriatrics, Geneva University Hospitals, Geneva, Switzerland K. Bouiller Department of Infectious Diseases, Besançon University Hospital, Besançon, France C. Serratrice · V. Prendki Division of Internal Medicine for the Aged, Geneva University Hospitals, Geneva, Switzerland C. Laborde · A. Fèvre Department of Geriatric Internal Medicine, Nimes University Hospital, Nimes, France V. Prendki Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland M. Gilis Department of Geriatrics, Besançon University Hospital, Besançon, France S. Sanchez Department of Clinical Research, Troyes Hospital, Troyes, France F. Hoefler · M. Bermejo Department of Internal Medicine and Infectious Diseases, Troyes Hospital, Troyes, France A. Putot (*) Service de Médecine Interne Gériatrie, Hôpital de Champmaillot CHU, 21079 Dijon Cedex, France e-mail: Vol.: (0123456789) 13 GeroScience more frequently transferred to the intensive care unit. In a large multicenter cohort of older inpatients with SARS-CoV-2 pneumonia, aspirin use before admission did not appear to be associated with an improved prognosis. Keywords Aspirin · Antiplatelet · Pneumonia · Coronavirus · COVID-19 · Aged · Mortality
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop